A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract

John Thomas Barrett; Bruno Orofiamma; Janardan D. Khandekar; Paul P. Carbone; Robert L. Comis; Thomas E. Davis

doi:10.1002/1097-0142(19891215)64:12<2445::AID-CNCR2820641208>3.0.CO;2-J

A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract

John Thomas Barrett, Bruno Orofiamma, Janardan D. Khandekar, Paul P. Carbone, Robert L. Comis, Thomas E. Davis

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval: 0.01, 0.35), whereas four of 20 (20%) responded on the VLB arm (95% confidence level: 0.06–0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46% of patients given VLB developing severe or life‐threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract. Cancer 64:2445–2447, 1989.

Original language	English (US)
Pages (from-to)	2445-2447
Number of pages	3
Journal	Cancer
Volume	64
Issue number	12
DOIs	https://doi.org/10.1002/1097-0142(19891215)64:12<2445::AID-CNCR2820641208>3.0.CO;2-J
State	Published - Dec 15 1989
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1097-0142(19891215)64:12<2445::AID-CNCR2820641208>3.0.CO;2-J

Cite this

@article{3e4bbb87092445809b22e6b2dcf3fa18,

title = "A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract",

abstract = "This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval: 0.01, 0.35), whereas four of 20 (20%) responded on the VLB arm (95% confidence level: 0.06–0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46% of patients given VLB developing severe or life‐threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract. Cancer 64:2445–2447, 1989.",

author = "Barrett, {John Thomas} and Bruno Orofiamma and Khandekar, {Janardan D.} and Carbone, {Paul P.} and Comis, {Robert L.} and Davis, {Thomas E.}",

year = "1989",

month = dec,

day = "15",

doi = "10.1002/1097-0142(19891215)64:12<2445::AID-CNCR2820641208>3.0.CO;2-J",

language = "English (US)",

volume = "64",

pages = "2445--2447",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "12",

}

TY - JOUR

T1 - A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract

AU - Barrett, John Thomas

AU - Orofiamma, Bruno

AU - Khandekar, Janardan D.

AU - Carbone, Paul P.

AU - Comis, Robert L.

AU - Davis, Thomas E.

PY - 1989/12/15

Y1 - 1989/12/15

N2 - This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval: 0.01, 0.35), whereas four of 20 (20%) responded on the VLB arm (95% confidence level: 0.06–0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46% of patients given VLB developing severe or life‐threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract. Cancer 64:2445–2447, 1989.

AB - This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval: 0.01, 0.35), whereas four of 20 (20%) responded on the VLB arm (95% confidence level: 0.06–0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46% of patients given VLB developing severe or life‐threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract. Cancer 64:2445–2447, 1989.

UR - http://www.scopus.com/inward/record.url?scp=0024815720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024815720&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19891215)64:12<2445::AID-CNCR2820641208>3.0.CO;2-J

DO - 10.1002/1097-0142(19891215)64:12<2445::AID-CNCR2820641208>3.0.CO;2-J

M3 - Article

C2 - 2684384

AN - SCOPUS:0024815720

SN - 0008-543X

VL - 64

SP - 2445

EP - 2447

JO - Cancer

JF - Cancer

IS - 12

ER -

A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this